|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/00 | (2006.01) |
| A61K 9/146 | (2013.01) | ||
| A61K 9/14 | (2006.01) | ||
| A61K 31/4439 | (2013.01) | ||
| A61K 9/20 | (2006.01) | ||
| A61K 9/2054 | (2013.01) | ||
| A61K 31/4439 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 35/04 | (2006.01) | ||
| A61K 9/0053 | (2013.01) | ||
| A61K 9/141 | (2013.01) | ||
| A61K 9/2027 | (2013.01) |
| (11) | Number of the document | 3925598 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21175525.1 |
| Date of filing the European patent application | 2015-12-03 | |
| (97) | Date of publication of the European application | 2021-12-22 |
| (45) | Date of publication and mention of the grant of the patent | 2025-02-12 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 14196605 | 2014-12-05 | EP |
| (72) |
VERRECK, Geert , BE
|
| (73) |
Aragon Pharmaceuticals, Inc. ,
10990 Wilshire Blvd. Suite 440, Los Angeles, CA 90024,
US
|
| (54) | ANTICANCER COMPOSITIONS |
| ANTICANCER COMPOSITIONS |